RxDoctor Payments Data

Tammy Wheeler, PA

Physician Assistant · Saratoga Springs, NYNPI 1063594067

Payments from drug & device makers

$8,834in general payments, 2019–2025

Across 460 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$1K
  • Novo Nordisk$1K
  • AstraZeneca$682
  • Amgen$534
  • Astellas Pharma US Inc$450
  • plus $4K from 34 others

What the payments were for

  • Speaking & faculty fees$4405%
  • Food & beverage$8,39495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,834 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$106,924
Medicare patients
287
Services billed
2,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$118,538
JardianceEmpagliflozin95$98,619
MounjaroTirzepatide57$71,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$53,643
EliquisApixaban37$29,202
FarxigaDapagliflozin Propanediol28$28,074
RybelsusSemaglutide24$24,276
MyrbetriqMirabegron42$21,064
AptiomEslicarbazepine Acetate13$17,699
JanuviaSitagliptin Phosphate24$16,283
LinzessLinaclotide25$15,786
XareltoRivaroxaban16$15,291
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$11,476
Emgality PenGalcanezumab-Gnlm12$10,677
Baclofen161$10,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,045$142,814122 claims
Boehringer IngelheimJardiance$401$98,61995 claims
Lilly USA, LLCMounjaro$347$71,98757 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,057$66,078110 claims
PfizerEliquis$312$29,20237 claims
AstraZenecaFarxiga$682$28,07428 claims
MerckJanuvia, Lagevrio (Eua)$76$24,03035 claims
Astellas Pharma US IncMyrbetriq$450$21,06442 claims
AbbVieLinzess$1,237$15,78625 claims
Johnson & JohnsonXarelto$105$15,29116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →